In COX multivariate analysis, elevated AMC remained as an independent prognostic factor for worse OS (HR, 1.578; 95% CI, 1.120 to 2.223, p=0.009). Conclusions: Our results indiicate that circulating AMC is confirmed to be an independent prognostic factor for OS in patients with locally advanced or metastatic HCC receiving systemic chemotherapy.
Introduction
Hepatocellular carcinoma (HCC), mostly originating in the context of chronic viral hepatitis and cirrhosis, remains the leading cause of death from cancer in the world (Jemal et al., 2011; Gao et al., 2012) . At the time of diagnosis or after disease progression, the majority of patients with HCC present with advanced-stage disease unsuitable for established local and regional therapies (Cui et al., 2012; Norsa'adah et al., 2013; . Given low response rates and no demonstrated survival benefit, systemic chemotherapy is not yet established as a standard treatment option for metastatic HCC (Louafi et al., 2007; Qin et al., 2013; He et al., 2013) . However, the fact is that systemic chemotherapy is widely employed in an effort to lessen cancer progression, especially in developing countries which are commonly unable to afford the established effective treatment with sorafenib (Cheng et al., 2009; Wang et al., 2013) . The prognostic significance of systemic inflammatory reaction in cancer patients has been extensively investigated. As an example, high level of peripheral blood inflammatory biomarkers including C-reactive protein and neutrophil-to-lymphocyte ratio was reported to be associated with inferior prognosis in patients with a variety of malignancies (Zheng et al., 2013; Yu et al., 2013; Jin et al., 2014) . Likewise, a large number of studies have revealed that peripheral blood absolute monocyte count (AMC) is considered as an independent prognostic factor in a range of malignancies, including early-stage HCC undergoing curative resection (Sasaki A et al., 2006; Lee et al., 2012; Huang et al., 2013; Li et al., 2013) . To date, the prognostic significance of circulating AMC in patients with advanced HCC is still uncertain. Hence, this study was designed to assess the association of circulating AMC with survival outcomes in patients diagnosed with locally advanced or metastatic HCC receiving systemic chemotherapy.
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Materials and Methods
Ethics statement
This study was approved by the ethics committee of Zhongshan Hospital of Sun Yat-sen University. And written informed consent was obtained from all patients prior to treatment.
Study design and patients
The study was performed to include patients with advanced HCC at Zhongshan Hospital of Sun Yat-sen University between January 2005 and December 2012. Eligible patients had histologically, cytologically, or clinically diagnosed locally advanced or metastatic HCC unsuitable for local and regional therapies; had Child-Pugh stage A or B disease; and received systemic chemotherapy.
Chemotherapy regimens in the present study encompassed single agent like 5-fluorouracil (continuous intravenous (IV) 200 mg/m 2 /d x 21, every 4 weeks) or doxorubicin (50 mg/m 2 IV on day 1, every 3 weeks) and combinations such as mFOLFOX6 (oxaliplatin 85 mg/ m 2 IV on day 1; leucovorin 400 mg/m 2 IV on day 1; and 5-fluorouracil 400 mg/m 2 IV bolus, then 2400 mg/m 2 continuous IV over 46 hours on day 1, every 2 weeks) or GEMOX (gemcitabine 1000 mg/m 2 IV on days 1 and 8 plus oxaliplatin 130 mg/m 2 IV on day 1, every 3 weeks). All while blood cell and differential counts were examined by the automated hematology analyzer Sysmex XE-2100 (Sys-mex, Japan) on the day before chemotherapy.
Baseline clinical features including gender, age, extrahepatic metastasis, Child-Pugh stage, serum alphafetoprotein (AFP) level and AMC were collected to investigate their prognostic impacts on overall survival (OS).
Statistical analysis
Receiver operating characteristic (ROC) curve analysis was conducted to identify the optimal cut-off values of AMC according to the maximum joint sensitivity and specificity. Chi-squared test was used to compare baseline clinical characteristics in different AMC groups. OS was characterized by the time from the date of treatment initiation to death, irrespective of cause. Survival curves were made using the Kapla-Meier method and compared by the log-rank test. Univariate and multivariate analysis to identify prognostic predictors were performed by Cox proportional hazard regression models. All abovementioned statistical analysis was conducted by SPSS 16.0 software (SPSS, Chicago, IL, USA). A two-tailed p<0.05 was regarded as significant.
Results
A total of 263 patients were included for the study, among whom, 47 patients were excluded due to accompanying active bacterial infections at diagnosis or incomplete research information, leaving 216 patients eligible for further analysis. The median age was 64.8 years (range 31-76 years). The ratio of male to female was 1.57:1 (132:84). 148 patients (68.5%) were documented to have extrahepatic metastasis. Child-Pugh stage A disease was found in 125 patients (57.8%). The mean serum AFP level at diagnosis was 3954 ng/ml (rang 613 to 17654 ng/ ml). The mean pretreatment AMC were 0.43 x10 9 /L (rang 0.01-5.46 x 10 9 /L). All patients were followed up until December 30, 2013, the median follow-up time was 6.9 months (range 1.2-8.9 months).
Based on the ROC curve, the optimal cut-off value of AMC for OS analysis was 0.38x10 9 /L, with a sensitivity of 71.2% and a specificity of 64.6%. According to the best cut-off value, 128 patients were assigned to low-(AMC <0.38x10 9 /L) AMC group while the remaining 88 patients were categorized into high-(AMC≥0.38 x10 9 /L) AMC arm. Comparison of baseline clinical characteristics according to pre-treatment AMC level is presented in Table 1 . No meaningful difference was noted between both AMC groups with respect to age, extrahepatic metastasis, Child-Pugh stage and serum AFP level. However, the Table 2. recruitment of immune cells to the liver and promote proliferation of inflammatory cells and hepatocytes, resulting in cirrhosis and finally malignant transformation of hepatocytes (Farazi et al., 2006; Castello et al., 2010) . As a sequence, HCC is an example of inflammationrelated cancer.
The current study showed that elevated AMC was significantly associated with worse OS in patients with locally advanced or metastatic HCC undergoing systemic chemotherapy, suggesting that circulating AMC appeared to be an independent prognostic parameter. Our findings is completely consistent with previously reported studies which demonstrated that increased AMC predicted inferior survival in early-stage HCC, nasopharyngeal carcinoma and cervical cancer (Sasaki et al., 2006; Lee et al., 2012; Li et al., 2013) . Currently, although growing evidence clearly confirms the prognostic significance of AMC in the above-mentioned malignancies, the exact mechanism for the interaction between monocytes and HCC is not yet fully addressed. Fortunately, recent studies, which mainly focused on molecular pathways involving in the development and progression of cancer, provide a valuable insight into the understanding of underlying mechanism. A large body of studies have highlighted that a range of HCC-derived cytokines including chemokine ligand 2 and macrophage colonystimulating factor promote recruitment of peripheral blood monocytes into tumor microenvironment and subsequently differentiation into mature macrophages which are designated as tumor-associated macrophages (TAMs) (Benetti et al., 2008; Zhu et al., 2008; Takai et al., 2009) . Furthermore, activated TAMs in turn establish a distinct inflammatory microenvironment responsible for stimulating proliferation, invasion, metastasis and angiogenesis of HCC (Peng et al., 2005; Schimanski et al., 2006; Liu et al., 2008; Kuang et al., 2010; Werno et al., 2010; Chen et al., 2012) . It is reasonable to believe that the vicious circle between HCC and TAMs is the driving engine of HCC for its continuous deterioration.
Our study also indicated that baseline clinical features including concurrent extrahepatic metastasis, serum AFP level and Child-Pugh stage were identified as independent prognostic factors in advanced HCC. This is in line with previously reported results (Yang et al., 2007; Gomaa et al., 2014) .
Although the sample size of the present study is relatively large, selection bias were difficult to be well balanced owing to the major limitation of its retrospective nature. Therefore, caution should be taken in interpreting the results.
In summary, our results indicate that circulating AMC is confirmed to be an independent prognostic factor for OS in patients with locally advanced or metastatic HCC receiving systemic chemotherapy. 
Discussion
To our knowledge, the present study is the first retrospective study to explore the prognostic significance of peripheral blood AMC in locally advanced or metastatic HCC treated with systemic chemotherapy, implicating that circulating AMC was confirmed to be an independent prognostic indicator for OS.
It is widely accepted that HCC typically originates from chronic viral hepatitis. A large body of case control studies and cohort studies have highlighted that chronic infections with hepatitis virus B and C contribute to increased risk for the development of HCC (Yang et al., 2002; Lok et al., 2009 ). However, the precise mechanism for the tumorigenesis of HCC attributable to chronic hepatitis B and C is complicated. It is believed that infections with hepatitis virus B and C generally cause
